Managing drug shortages in Australian pharmacy

Managing drug shortages is a resilience task for Australian pharmacists, not simply a purchasing problem. A medicine may be unavailable because production has paused, wholesaler stock is limited, pack sizes have changed or local demand has risen. Every disruption can interrupt therapy. Priorities are to prevent avoidable harm, maintain access and explain the available choices clearly.

Australian pharmacies operate in a market shaped by the Pharmaceutical Benefits Scheme, Therapeutic Goods Administration (TGA), wholesalers, sponsors and state and territory pharmacy laws. PBS listing, patient co-payments and possible authority requirements can complicate a clinically suitable swap. A stockout in Sydney or Melbourne can be brief, while regional New South Wales or the Northern Territory may face longer transport lead times. Local demand, courier capacity and remaining pack sizes matter alongside national shortage advice.

Substitution requires more than selecting the nearest product. Compare active ingredient, strength, dose, formulation, route and intended use. Insulin, anticoagulants, anti-epileptics, antibiotics, opioids and psychiatric medicines need particular caution. Excipients, modified-release properties and dosing schedules can affect allergies, swallowing, pregnancy, kidney function and monitoring. A convenient package swap may still be unsafe.

An effective response links verification, clinical review, communication and continuity. Give the team a named coordinator, define substitution authority and record the evidence behind each decision. Establish when patients, prescribers, aged-care staff and supply partners will be contacted. The aim is not to promise that every medicine will remain available; it is to provide a safe alternative before uncertainty causes missed doses or fragmented care.

Treat every shortage as a patient-safety event

Treat every drug shortage as a patient-safety event, then grade its urgency. One missing antibiotic may affect many people, while interrupted insulin, anticoagulation, seizure control, opioid treatment or relapse prevention can cause rapid harm. Consider the number of patients, expected duration, available alternatives and clinical vulnerability. A prolonged shortage with safe options differs from a brief interruption with no equivalent substitute.

Search the dispensing system and physical stock before changing therapy. Check every on-hand quantity, unclaimed repeat, discontinued line and transfer option. Establish whether the problem is a brand, strength, formulation or active ingredient. Record batch numbers and expiry dates, particularly when quality may be involved. Allocate stock fairly and preserve clinically urgent quantities without allowing unnecessary hoarding.

Escalate high-risk failures on the day they are identified. Use current Australian Government shortage information, TGA product records, sponsor advice and wholesaler updates to establish national and local status. Follow relevant reporting pathways and state or territory requirements. Contact patients whose ongoing repeats are at risk; silence may lead them to stop treatment. Record each contact so another pharmacist can continue the plan.

Verify supply and clinical facts

Verify the shortage before announcing a solution. Compare the missing product, strength, presentation and pack size with the Australian Register of Therapeutic Goods, current government shortage information and the sponsor’s latest advice. A wholesaler allocation problem may resemble a national shortage without being one. Ask about quantities and dates, confirm local stock, and schedule repeat checks rather than relying on informal messages.

Then verify patient-specific facts: indication, age, weight where relevant, renal and hepatic function, allergies, other medicines, pregnancy, swallowing ability and monitoring. Confirm the intended therapy and documented past responses. Records can contain old brand directions or incomplete histories. Reconcile the prescription and supply history, especially after hospital discharge or aged-care transition, before choosing an alternative.

Create a temporary plan for each medicine. State the preferred substitute, accepted alternatives, cases needing prescriber approval, maximum quantity, review date and escalation trigger. Include PBS availability, dispensing rules and special controls. Keep it visible to every dispensing location and update it when stock or guidance changes. A current, owned plan beats a detailed folder that staff never see.

Choose substitutions with clinical precision

Use a clinical hierarchy rather than price or shelf position. Start with the same active ingredient and strength in an approved alternative brand or formulation, then consider a therapeutic alternative supported by guidelines and prescriber intent. Dose conversion may be needed. Reserve compounding or unapproved supply for defined circumstances in which law, quality, stability and clinical governance have been addressed.

Seek prescriber agreement for insulin, warfarin and other anticoagulants, lithium, anti-epileptics, methotrexate, transplant medicines, narrow therapeutic index drugs and time-critical antibiotics, unless an approved collaborative arrangement already covers the change. For Schedule 8 medicines, follow the relevant state or territory permit, records and storage requirements. A shortage does not remove those controls.

Review excipients and formulation, not only the active ingredient. Lactose, gluten, dyes, preservatives, sugar and modified-release properties can affect suitability. Check paediatric needs, injectable compatibility and devices such as insulin pens. An older-patient exanthem review offers background on drug eruptions in older adults. A new rash, breathing difficulty or facial swelling needs prompt medical assessment through local emergency pathways.

Compounding can fill a genuine gap but needs a valid prescription, suitable ingredients, quality control, storage advice and a stability assessment. Do not treat a compounded product as interchangeable without review. Do not recommend online purchases of unapproved medicines: overseas supply may involve Australian Customs, biosecurity and TGA rules and may not meet Australian quality or cold-chain expectations.

Build a clear communication rhythm

Build a regular communication rhythm. Hold a short daily huddle, nominate one pharmacy lead and agree the message for patients, prescribers and other branches. Staff need the current fact, available stock, approved options and escalation route at a glance. A pharmacy leadership perspective can support role clarity, psychological safety and feedback during disruption, while local protocols remain authoritative.

Use a structured format for prescribers. State the situation and affected product, provide relevant background and the expected supply timeline, assess urgency, and propose a specific option with evidence. “Same, but generic” is insufficient. Identify any changed strength, formulation, excipient, schedule or monitoring need. Obtain an authorised plan and document the response, including a decision not to change.

Explain choices in plain English without claiming that medicines sharing an ingredient are identical in every respect. Say why the usual product is unavailable, what will be supplied, how to take it, what may change and when the pharmacy will call again. Use a qualified interpreter and accessible written information when needed. Ask the patient to repeat the plan, then provide written contact details.

Coordinate decisions across the care team

Treat coordination as more than a call to the usual prescriber. Alert hospital pharmacy, community mental-health services, aged-care workers, home-health nurses and palliative-care teams when their supply is affected. State who must act and by when. This prevents one clinician assuming another has approved a substitute, especially during transitions of care.

Share information through secure systems. AusLAN can support medication-event communication between participating providers, while electronic prescriptions and pharmacy records should be checked for currency. An old entry may not identify a new strength or schedule. Maintain privacy, send only necessary details and confirm receipt. In areas with weak connectivity, use the region’s approved telephone or fax pathways.

When clinicians disagree, move to a formal escalation pathway. Ask a specialist, medicines committee or accredited pharmacist to review the evidence, define the risks of waiting and set a reassessment time. For urgent deterioration, direct the patient to appropriate emergency care rather than prolonging debate. Keep the patient informed, then update every relevant record so the agreed plan continues after the first supply.

Protect continuity across the Australian market

Protect continuity across the PBS and local market. Use PBS online systems correctly, check listed brands and authority requirements, and tell patients when a suitable replacement may change their out-of-pocket cost. A non-PBS alternative may require a new prescription or prescriber action. Establish lawful transfer arrangements for travellers and reserve urgent quantities through a transparent allocation policy.

Plan for distance, weather and cold-chain risk. An outer Melbourne pharmacy may collect courier stock quickly, while shortages in Perth, Adelaide, regional Queensland or remote Northern Australia can require longer planning. Confirm courier days, dangerous-goods rules and temperature handling before promising supply. Transfer usable stock before expiry rather than discarding it, and combine metropolitan demand with remote transport constraints in forecasts.

Use staged measures: smaller clinically meaningful quantities, an authorised substitute, repeat supply where permitted, compounding through an approved pathway or transfer to another location with stock. Reassess at each stage because wholesale availability can change quickly. For medicines affecting addiction treatment, seizure control or mental health, avoid abrupt interruption and coordinate changes with the treating team. Give a clear follow-up date.

Document outcomes and strengthen readiness

Document the shortage, proposed change and clinical reasoning. Record the verification source and time, stock checked, prescriber contact, patient agreement, selected product, batch, quantity and review date. Report medicine-related harm through TGA pharmacovigilance and significant operational incidents through pharmacy governance. A near miss should trigger review just as a dispensing error does. Records protect continuity when another pharmacist takes over.

Measure outcomes as well as stock levels. Useful indicators include time to verification, patients contacted, time to approved substitution, missed doses, repeat calls, out-of-stock substitutions and wastage. Review results with the team and seek feedback from prescribers, patients and aged-care partners. Update the playbook, supplier agreements, stock parameters and training from what the event reveals.

Include workforce wellbeing. Repeated triage and difficult conversations can increase fatigue and errors in a small team. Use a clear rota, competent backup and a channel for escalating pressure. Treat dependence-related and mental-health concerns with dignity, because interrupted medicines can increase withdrawal, distress or safety risk. Regular simulations build a tested team capability rather than relying on one person’s memory.

Create or update a one-page shortage playbook now. Name the pharmacy lead, information sources, substitution authority, high-risk list, prescriber message, patient script, documentation fields and escalation contacts. Load current contacts into the operating system and brief every staff member before the next busy period. Test the playbook with one commonly interrupted medicine, then adapt it to the pharmacy’s location and patient mix.

Keep a live shortage board, review it daily while supply is disrupted and close the event only after affected patients and partners have documented follow-up. Build relationships with local prescribers, wholesalers, hospitals and neighbouring pharmacies before a crisis, and communicate openly throughout it. This rhythm keeps access, clinical governance and patient trust aligned when the market cannot supply the usual product.